Cytoreduction with azacitidine (AZA) prior to non-myeloablative transplantation in patients with myelodysplastic syndromes (MDS) has no effect on transplant outcomes, according to a multi-center study comparing patients who received AZA (n=40) and patients who did not (n=88). At diagnosis, 55 patients had intermediate-2 or high-risk IPSS scores, and 33 had a high cytogenetic risk score. At a median follow-up of 60 months for the AZA group and the non-AZA group, 3-year overall survival, relapse-free survival, cumulative incidence of relapse, and non-relapse mortality were 53% vs. 53% (p=0.69), 37% vs. 42% (p=0.78), 35% vs. 36% (p=0.99), and 20% vs. 23% (p=0.74), respectively.
No Effect of Pre-HCT Cytoreduction in MDS
Jun 2014